Condition: Lymphatic Malformation · Pediatric · Sponsor: University Hospital, Lille
To evaluate the efficacy of Rapamycin in extended cervicofacial lymphatic malformations in pediatric patients. Rapamycin is administered oral for a 6 month period. The success rate is determined by volume reduction superior to 1/5e of the initial volume measured by MRI, impact on QOL and reduction of bleeding in case of mucosal involvement.
This description comes directly from the study's public registry record.
Pierre Fayoux, MD · 3 20 44 50 67 · pierre.fayoux@chru-lille.fr
Always discuss trial participation with your own doctor first.
| Hôpital Jeanne de Flandres, CHU | Lille, France | Recruiting |
| Hu Robert Debre Aphp - Paris | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03243019